ES2156444T3 - Nuevos compuestos. - Google Patents

Nuevos compuestos.

Info

Publication number
ES2156444T3
ES2156444T3 ES98924708T ES98924708T ES2156444T3 ES 2156444 T3 ES2156444 T3 ES 2156444T3 ES 98924708 T ES98924708 T ES 98924708T ES 98924708 T ES98924708 T ES 98924708T ES 2156444 T3 ES2156444 T3 ES 2156444T3
Authority
ES
Spain
Prior art keywords
pct
sec
new compounds
date
pub
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98924708T
Other languages
English (en)
Inventor
Nicholas Kindon
Premji Meghani
Stephen Thom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2156444T3 publication Critical patent/ES2156444T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal (AREA)
  • Valve-Gear Or Valve Arrangements (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de fórmula I o una sal del mismo: (I) **fórmula** en la cual: A es un anillo heterocíclico de 5 miembros que contiene 1 a 3 heteroátomos seleccionados de nitrógeno, oxígeno o azufre; R1 es (CH2)nCO2H donde n es 1 ó 2, (CH2)q tetrazol-5-ilo donde q es 0, 1 ó 2 o R1 es COR3 donde R3 es amino, alquilamino, dialquilamino, NHOalquilo, NHSO2alquilo, OH, N(CH2CO2H)2 o un grupo de fórmula (i): (i) **fórmula** en la cual p es 1 ó 2, o R 3 es un grupo de fórmula (ii): (ii) **fórmula** donde B es un anillo heterocíclico de 5 miembros que contiene 1a 4 heteroátomos seleccionados de nitrógeno, oxígeno o azufre y R8 es hidrógeno o un grupo CH2CO2H, CH2CON(CH2CO2H)2 o CH2COR9 donde R9 es un grupo de fórmula (i) como se ha definido anteriormente o un grupo de fórmula (iii): **fórmula** R2 es un grupo de fórmula (iv) o (v): (iv) **fórmula** (v) **fórmula** donde los grupos R4 son independientemente hidrógeno, halógeno, metoxi, metiltio o alquilo C1-2 (sustituido opcionalmente con uno o más átomos de fluor); los grupos R5 son independientemente hidrógeno, halógeno, hidroxi, alquiltio C1-3, alquilo C1-4 (sustituido opcionalmente con uno o más átomos de fluor), cicloalquilo C3-4, MeOCH2, MeSCH2 o alcoxi C1-2; los grupos R6 son independientemente hidrógeno, halógeno o metilo (sustituido opcionalmente con uno o más átomos de fluor); Z1 es CH=CH, CF=CH o CF=CF; Z2 es un enlace simple, oxígeno, azufre, CH2CH=CH, CH2CH=CHCH2 o un grupo alquileno C1-4 interrumpido opcionalmente por un átomo de oxígeno o de azufre; R7 es hidrógeno, halógeno, alquilo C1-2, CF3 o un grupo metiltio; Q1 y Q2 representan cada uno independientemente O o S; con la condición de que, cuando Q1 es oxígeno, R2 es un grupo de fórmula (iv).
ES98924708T 1997-05-28 1998-05-18 Nuevos compuestos. Expired - Lifetime ES2156444T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702002A SE9702002D0 (sv) 1997-05-28 1997-05-28 Novel compounds

Publications (1)

Publication Number Publication Date
ES2156444T3 true ES2156444T3 (es) 2001-06-16

Family

ID=20407125

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98924708T Expired - Lifetime ES2156444T3 (es) 1997-05-28 1998-05-18 Nuevos compuestos.

Country Status (12)

Country Link
US (1) US6162808A (es)
EP (1) EP0984963B1 (es)
JP (1) JP2002501528A (es)
AT (1) ATE200489T1 (es)
AU (1) AU7681198A (es)
DE (1) DE69800699T2 (es)
DK (1) DK0984963T3 (es)
ES (1) ES2156444T3 (es)
GR (1) GR3036195T3 (es)
PT (1) PT984963E (es)
SE (1) SE9702002D0 (es)
WO (1) WO1998054180A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2172939T3 (es) * 1997-11-21 2002-10-01 Astrazeneca Uk Ltd Nuevos compuestos que son antagonistas de receptores acoplados a proteina g de 7-transmembrana (tm) de p2-purinoceptores.
US7696168B2 (en) * 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
WO2001081408A2 (en) 2000-04-21 2001-11-01 New England Medical Center G-protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
US20030151980A1 (en) * 2002-02-13 2003-08-14 Isador Farash Color referenced multi-time watch
AUPS160602A0 (en) 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis
US8440627B2 (en) * 2004-11-04 2013-05-14 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of use
US7589213B2 (en) 2007-04-27 2009-09-15 Old David W Therapeutic substituted lactams
US8592413B2 (en) 2008-05-15 2013-11-26 Allergan, Inc. Therapeutic substituted cyclopentanes
CN103159641A (zh) * 2011-12-14 2013-06-19 天津泰普药品科技发展有限公司 托伐普坦中间体2-甲酸-5-(2-甲基苯甲酰氨基)甲苯的制备方法
EP2881390A1 (en) 2013-12-04 2015-06-10 Sanofi Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase
CN106045937B (zh) * 2016-06-21 2019-04-16 杭州诺维和医药技术有限公司 一种{2-[2-(2-氨基-4-噻唑基)-乙酰基氨基]-4-噻唑基}-乙酸的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2099868C (en) * 1991-01-31 2002-04-02 Thomas Richard Belliotti Substituted 4,6-di-tertiary-butyl-5-hydroxy-pyrimidines
IT1277373B1 (it) * 1995-07-28 1997-11-10 Consiglio Nazionale Ricerche Impiego di composti agonisti o antagonisti dei recettori purinici p2 per la prevenzione della citotossicita' da glutammato

Also Published As

Publication number Publication date
WO1998054180A1 (en) 1998-12-03
DE69800699D1 (de) 2001-05-17
SE9702002D0 (sv) 1997-05-28
GR3036195T3 (en) 2001-10-31
US6162808A (en) 2000-12-19
ATE200489T1 (de) 2001-04-15
DE69800699T2 (de) 2001-09-06
EP0984963B1 (en) 2001-04-11
PT984963E (pt) 2001-07-31
AU7681198A (en) 1998-12-30
EP0984963A1 (en) 2000-03-15
DK0984963T3 (da) 2001-06-05
JP2002501528A (ja) 2002-01-15

Similar Documents

Publication Publication Date Title
SE9702651D0 (sv) Novel compounds
BR0015963A (pt) Compostos de uréia antagonistas receptor muscarìnico, composições farmacêuticas compreendendo tais compostos e método de preparação destes compostos
EP0903349A3 (en) CCR-3 receptor antagonists
DE69532162D1 (de) Cannabinoid-rezeptor-antagonisten
ATE331726T1 (de) Adenine-derivate
ES2160525A1 (es) Derivados de la 4-aroilpiperidina antagonistas de los receptores ccr-3
WO2003086303A3 (en) Farnesoid x-activated receptor agonists
DE60012040D1 (de) Trizyklische 1-benzylpyrazol-3-carbonsäurederivate als cannabinoidrezeptorantagonisten
ES2158813A1 (es) Sales cuaternarias de piperidina antagonistas del receptor ccr-3
SE9702002D0 (sv) Novel compounds
SE9702794D0 (sv) New compounds
ES2172939T3 (es) Nuevos compuestos que son antagonistas de receptores acoplados a proteina g de 7-transmembrana (tm) de p2-purinoceptores.
FR2690847B1 (fr) Compositions a activite agoniste des recepteurs analogues a 5ht1 selective.
NO995685L (no) Nye glycosylerte ginkgolidderivater, anvendelse derav som medikamenter og farmasoeytiske blandinger
EA200300850A1 (ru) Применение антагонистов рецептора gal3 при лечении депрессии и/или тревоги и соединения, полезные в таких способах
NO20000654D0 (no) 1,3-dioxolo/4,5-H//2,3/benzodiazepinderivater som AMPA/KAINAT reseptorinhibitorer
DE69526738D1 (de) Endothelin-rezeptor-antagonisten
ECSP972049A (es) Derivados de lactama

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 984963

Country of ref document: ES